We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




N-acetylcysteine Protects Dopamine-Producing Neurons from Stress Damage and Eases Parkinson's Symptoms

By LabMedica International staff writers
Posted on 27 Jun 2016
A preliminary clinical study demonstrated the effectiveness of n-acetylcysteine (NAC) in promoting survival of neurons and alleviating symptoms in patients with Parkinson's disease (PD).

Previous studies have shown that oxidative stress in the brain may play an important role in the Parkinson's disease process, and that this stress reduces levels of the antioxidant glutathione. More...
NAC acts to reduce oxidative damage to neurons by restoring glutathione levels.

The purpose of the clinical study carried out by investigators from Thomas Jefferson University (Philadelphia, PA, USA) was to explore the effects of NAC using both an in vitro and in vivo approach. To find supportive data for the pilot clinical study, the investigators performed a cell line tissue culture study in which they used a model of PD that employed midbrain dopamine (mDA) neurons generated from human embryonic stem cells (hESCs) to determine whether NAC could protect these mDA neurons from damage resulting from exposure to increasing doses of the PD-like neurotoxin, rotenone.

In the clinical study, patients continued their standard of care and were randomized to receive either daily NAC, alternating between oral and IV administration, or no NAC. Patients were evaluated before and after three months of receiving NAC with DaTscan to measure dopamine transporter (DAT) binding and the Unified Parkinson’s Disease Rating Scale (UPDRS) to measure clinical symptoms.

Results published in the June 16, 2016, online edition of the journal PLOS One revealed that in the cell line study NAC exposure resulted in significantly more mDA neurons surviving after exposure to rotenone compared to no NAC, consistent with the protective effects of NAC previously observed. In the clinical trial the patients receiving NAC had improvements of 4-9% in dopamine transporter binding and about a 13% improvement in their UPDRS score as compared to untreated control patients.

"This study reveals a potentially new avenue for managing Parkinson's patients and shows that n-acetylcysteine may have a unique physiological effect that alters the disease process and enables dopamine neurons to recover some function," said senior author Dr. Daniel Monti, professor of integrative medicine at Thomas Jefferson University.

Related Links:
Thomas Jefferson University



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.